CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026

Phase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancerUpdated data show universal CCR5 expression, early ctDNA reductions and favorable tolerability VANCOUVER, Washington, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including co